{"title":"Novel immunotherapy combinations in head and neck squamous cell carcinoma.","authors":"Shyam Kankotia, Soyun Park, Jacob Thomas","doi":"10.1097/CCO.0000000000001127","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a deadly disease that historically was treated with palliative chemotherapy-based regimens. Since 2019, immunotherapy-based regimens have become the standard of care for 1 st line treatment in this disease. Over the last several years, there have been numerous studies conducted with novel combination therapies for R/M HNSCC but there has not yet been a new standard of care.</p><p><strong>Recent findings: </strong>Novel treatment combinations with chemotherapy, targeted therapy, immunotherapy, vaccines, and intratumoral drugs have been evaluated in the treatment of R/M HNSCC. Favorable efficacy has been seen with many of these combinations, although some large studies have failed to improve upon the current standard.</p><p><strong>Summary: </strong>Many promising combination regimens are being tested which could lead to a new standard of care in the treatment of R/M HNSCC in the coming years.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"209-217"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001127","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: Relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a deadly disease that historically was treated with palliative chemotherapy-based regimens. Since 2019, immunotherapy-based regimens have become the standard of care for 1 st line treatment in this disease. Over the last several years, there have been numerous studies conducted with novel combination therapies for R/M HNSCC but there has not yet been a new standard of care.
Recent findings: Novel treatment combinations with chemotherapy, targeted therapy, immunotherapy, vaccines, and intratumoral drugs have been evaluated in the treatment of R/M HNSCC. Favorable efficacy has been seen with many of these combinations, although some large studies have failed to improve upon the current standard.
Summary: Many promising combination regimens are being tested which could lead to a new standard of care in the treatment of R/M HNSCC in the coming years.
期刊介绍：
With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
